Gene · 4486
Papers1,924
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
521 to 540 of 1,924
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Aberrant Sialylation in Cancer: Biomarker and Potential Target for Therapeutic Intervention? | Cancers (Basel) | 2021 | 33921986 | PubTator, text mining | PubMed |
The Context-Dependent Impact of Integrin-Associated CD151 and Other Tetraspanins on Cancer Development and Progression: A Class of Versatile Mediators of Cellular Function and Signaling, Tumorigenesis and Metastasis. | Cancers (Basel) | 2021 | 33919420 | PubTator, text mining | PubMed |
| RTK Inhibitors in Melanoma: From Bench to Bedside. | Cancers (Basel) | 2021 | 33918490 | PubTator, text mining | PubMed |
| Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment. | Biomedicines | 2021 | 33918146 | PubTator, text mining | PubMed |
| SIPA1 Is a Modulator of HGF/MET Induced Tumour Metastasis via the Regulation of Tight Junction-Based Cell to Cell Barrier Function. | Cancers (Basel) | 2021 | 33917539 | PubTator, text mining | PubMed |
| Bioinformatic analysis linking genomic defects to chemosensitivity and mechanism of action. | PLoS One | 2021 | 33909629 | PubTator, text mining | PubMed |
| IL-4, IL-17 and CD163 Immunoexpression and IL-6 Gene Polymorphism in Chronic Hepatitis C Patients and Associated Hepatocellular Carcinoma. | Asian Pac J Cancer Prev | 2021 | 33906302 | PubTator, text mining | PubMed |
| Emerging strategies for treating metastasis. | Nat Cancer | 2021 | 33899000 | PubTator, text mining | PubMed |
| A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations. | Transl Lung Cancer Res | 2021 | 33889528 | PubTator, text mining | PubMed |
| Adding Another Piece to the Puzzle of Why NTM Infections Are Relatively Uncommon despite Their Ubiquitous Nature. | mBio | 2021 | 33879587 | PubTator, text mining | PubMed |
| Metatranscriptomics reveals the gene functions and metabolic properties of the major microbial community during Chinese Sichuan Paocai fermentation. | Food Microbiol | 2021 | 33875193 | PubTator, text mining | PubMed |
| Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase. | Ther Adv Med Oncol | 2021 | 33868463 | PubTator, text mining | PubMed |
| An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. | Nat Commun | 2021 | 33863885 | PubTator, text mining | PubMed |
| State of the structure address on MET receptor activation by HGF. | Biochem Soc Trans | 2021 | 33860789 | PubTator, text mining | PubMed |
| The use of proteomics for blood biomarker research in premature infants: a scoping review. | Clin Proteomics | 2021 | 33853516 | PubTator, text mining | PubMed |
| Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial. | PLoS One | 2021 | 33826614 | PubTator, text mining | PubMed |
| Prevalence and Risk Factors of Infection in the Representative COVID-19 Cohort Munich. | Int J Environ Res Public Health | 2021 | 33808249 | PubTator, text mining | PubMed |
| The Role of Immunogenetics in COVID-19. | Int J Mol Sci | 2021 | 33807915 | PubTator, text mining | PubMed |
| Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors. | Int J Mol Sci | 2021 | 33807608 | PubTator, text mining | PubMed |
| The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications. | Cancers (Basel) | 2021 | 33806258 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4486/papers?page=27